GRAIL — Third Quarter 2026 Earnings Summary

GRAIL reported third-quarter 2026 financial results with Galleri test revenue increasing 14% year-over-year to $37.3 million and total revenue rising 4% to $37.5 million. The company announced that an FDA Advisory Committee voted in favor of approving the Galleri multi-cancer early detection test, with a final FDA decision anticipated in early 2027. Clinical trial data published this quarter demonstrated substantially increased cancer detection rates and significant reductions in late-stage diagnoses compared to standard care. Despite commercial momentum, GRAIL reported a net loss of $103.6 million for the quarter and held $788.7 million in cash and short-term marketable securities as of September 30, 2026.